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A B S T R A C T
Background: Rapid molecular point-of-care tests (POCTs) for influenza have potential to produce cost savings in
emergency departments (EDs) and acute care settings. To date, published projected savings have been based on
estimated costs.
Objectives: This study aimed to describe the cost implications of a rapid influenza POCT using accurate real-
world patient level costing data. 204 adult patients receiving point-of-care (POC) influenza testing in the ED as
part of a routine clinical service were identified retrospectively, alongside a control cohort of 104 patients from
the same influenza season. Costs for all were calculated at the individual patient level. Cost comparison was
performed using an instrumental variable (IV) regression to overcome potential bias within the observational
dataset.
Results: Patients who had a POCT on average cost 67 % less than those who did not (average cost reduction:
£2066: 95 % CI: £624 and £2665). Moderate to high NEWS score at arrival, presence of≥1 comorbidity, and age
≥70 years increased overall costs across both groups (p < 0.05).
Conclusions: Savings from POC testing can be attributed to more targeted treatments, fewer admissions and
reduced lengths of stay. The IV regression results are supported by a second method (ordinary least square
against baseline characteristics). They are also in line with existing work that use estimated costs but indicate
greater savings than predicted previously. In conclusion, POC influenza testing in the emergency department
produces significant cost savings, this is demonstrated here through an analysis using individual real-world
patient level costing data.
1. Introduction
Influenza remains a major cause of morbidity and mortality in the
United Kingdom, creating significant pressure on healthcare services.
While cases can be identified upon clinical presentation, this approach
is recognised to have poor sensitivity [1]. Accurate diagnosis is crucial
to direct appropriate management and prevent nosocomial transmis-
sion.
Widely available molecular techniques, including polymerase chain
reaction (PCR), are highly sensitive and specific in identifying influenza
but traditionally required batched testing in specialist laboratories,
creating delays. Recently, molecular point-of-care tests (POCTs) have
become available which produce accurate results rapidly and require
minimal training to operate.
Several groups have attempted to evaluate the impact of point-of-
care (POC) influenza testing in emergency departments (EDs) and ad-
missions units within the UK National Health Service (NHS) [2–6].
These groups estimate cost savings through reduced lengths of stay,
reduced unnecessary isolation and increased targeted treatments.
However, so far, the economic implications of POCTs have not been
evaluated using real-world patient level data of costs incurred.
Building on existing literature, this study aims to accurately de-
scribe the cost implications of using a rapid influenza POCT (Roche
cobas® Liat®) in adults presenting to the ED by retrospectively
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comparing an intervention and control group within the same influenza
season and using real-world patient level costing data for each in-
dividual.
2. Materials and methods
2.1. Point of care testing
The Roche cobas® Liat® PCR system comprises an automated ana-
lyser and a single-use assay tube. We used a multiplex assay to detect
influenza A and B, with a manufacturer reported sensitivity of 100 %
for both species, and specificity of 96.8 % for influenza A, 94.1 % for
influenza B [7]. Multiple study groups have reproduced similar sensi-
tivity and specificity in controlled laboratory settings [8] and near-
patient environments [9,10]. The sensitivity and specificity are com-
parable to other similar POC systems [11–14].
Respiratory samples were collected using a swab then placed into
universal transport medium (UTM™). The manufacturer recommends
nasopharyngeal sampling; however, we used pharyngeal samples as
they were easier for staff to perform with minimal training and more
acceptable to patients [15]. Approximately 200 μL of the inoculated
UTM™ was transferred into the assay tube, sealed, then placed inside
the analyser. Real-time RT-PCR occurs within the closed system, pro-
ducing a result in 20 minutes. When possible, the remaining aliquot of
UTM™ was sent for confirmatory laboratory testing. Frontline ED staff
performed the testing; none had specialist laboratory skills.
2.2. Routine laboratory-based testing
Laboratory testing was performed at Leeds Teaching Hospitals mo-
lecular virology laboratory. An in-house multiplex PCR was used to
detect influenza A, influenza B, sub-typing of influenza A for H1 (H1N1
pdm09) and H3 (H3N2), respiratory syncytical virus, metapneumo-
virus, adenovirus, rhinovirus, parainfluenza 1–4 and Mycoplasma
pneumoniae, alongside an MS2 internal control. Further details are
available in the supplementary materials.
2.3. Site selection
Work took place at St. James’s University Hospital, part of Leeds
Teaching Hospitals NHS Trust in Leeds, United Kingdom, where this
POCT was being introduced for routine clinical service for the first time.
The Trust has 2494 inpatient beds, of which 160 are critical care. It
receives approximately 221,000 ED attendances per annum.
2.4. Selection of the intervention cohort
The intervention cohort were identified retrospectively and com-
prised the first 204 consecutive adult patients (> 16 years) presenting
to the ED between 20th December 2017 and 5th January 2018 and
receiving a POCT from the date of its introduction. This period im-
mediately preceded the peak of the influenza season [16]. Decision to
perform a POCT was made by the assessing clinician with support from
a simple algorithm, which advised testing any patient with symptoms of
influenza (fever, plus 2 or more of cough, sore throat, headache, rhi-
norrhoea, myalgia, vomiting and diarrhoea) or a clinical diagnosis of
pneumonia, lower respiratory tract infection or infective exacerbation
of chronic obstructive pulmonary disease (COPD). Of this cohort, 148
patients had confirmatory testing of their sample in the laboratory.
There were 11 discrepant results (see supplementary material, Table
S1) which we classified according to the final diagnosis decided upon
by the treating physicians, as this reflected the actual management
delivered.
2.5. Selection of the control cohort
A control cohort was identified retrospectively, opportunistically,
and pragmatically. For logistical reasons, between 15th and 25th
February 2018 no assay kits were available, so no POCTs were per-
formed. Patients attending the ED during this period who were tested
for respiratory viruses by laboratory-based PCR were therefore selected
as controls. Controls were identified from a list of all samples collected
between 15th February and 2nd March 2018 which received labora-
tory-based respiratory viral PCR testing. Although POCTs resumed on
26th February, a 5-day extension was incorporated to account for de-
lays in decisions to test. The incubation period of influenza is
24–72 hours [17] so this period was limited to 5 days. After excluding
patients< 16 years old and those who did not attend ED in the above
time frame, 104 controls resulted.
2.6. Calculation of patient level costing
The costs assigned to all activity in the intervention and control
cohorts were generated through the Leeds Teaching Hospitals patient
level information costing system (PLICS). This uses electronic data to
allocate a cost to each stage of a patient’s treatment pathway. The total
cost of each individual’s ED attendance and, when applicable, the
linked inpatient stay was calculated. This included variable costs
(radiology, pathology, pharmacy) and fixed costs (staffing, facilities). It
was not possible to find full costings for 13 individuals, possibly due to
coding or data errors. Our primary analysis excluded these individuals.
However, we assessed any potential impact of these missing data in a
secondary analysis by imputing the missing costs via multiple imputa-
tion analysis assuming missing at random.
2.7. Cost comparison between the intervention and control cohort
Exploring the treatment effect of an intervention where only ob-
servational data are available is challenging. Observational data have
not been randomised, therefore it is likely the average distribution of
observed and unobserved characteristics among participants will be
different. Consequently, an analysis via an ordinary least square (OLS)
regression to adjust total incurred costs with co-variates known to be
related to increased use of healthcare resources (e.g. length of stay,
intensive care) could mask the true impact of the intervention. Several
methods have been proposed to improve estimations of treatment effect
in observational data. These methods seek to mimic randomisation or
model directly the selection process to offer an unbiased treatment ef-
fect. Examples include OLS with baseline covariates, matching
methods, inverse probability weighting or instrumental variables (IV)
regression [18–20].
The IV method is the most common method to manage un-
observable factors. An IV will mimic the effect of randomisation by
identifying patients who should receive the intervention but will only
affect the outcome via the specified treatment. This allows us to es-
tablish causality. Finding an adequate instrument, however, can be
difficult [21]. Once an adequate instrumental variable is found, the IV
regression analysis is performed in a 2-stage OLS model. The first
evaluates the probability of being in the intervention arm: if the POCT
was available, would the patient have been offered it? The predicted
values of this regression analysis are then used to estimate the treat-
ment effect.
After reviewing the dataset, we found that provisional diagnosis
fulfilled IV criteria: predicting the probability of receiving the inter-
vention (being offered a POCT if available); but not being directly
correlated with the outcome (total cost of the hospital attendance). We
tested provisional diagnosis as an instrumental variable via an OLS
against total cost and found no correlation between the two, confirming
its adequacy for use (supplementary material, Table S4). We also esti-
mated the treatment effect via an OLS regression against baseline
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control characteristics only, to test the validity of our IV regression
analysis. This method avoids potential contamination between the
treatment and the outcome.
3. Results
Table 1 describes the baseline characteristics of the analysed po-
pulation. Table 2 outlines the final diagnoses, alongside the proportion
who were admitted for inpatient care, their length of stay, and the
proportion who received antivirals.
In the initial OLS analysis, using well-known co-variates and pro-
visional diagnosis to adjust for potential heterogeneity in our popula-
tion showed a significant and positive relationship between total costs
of the hospital attendance and length of stay, inpatient care, and in-
tensive care admission (Table S4, supplementary materials). However,
having the POCT (or being in the intervention group) was associated
with an increase in total costs of hospital attendance by 34 % on
average, despite a lower proportion of patients requiring inpatient care,
intensive care and having shorter length of stays (Table 2). This in-
dicates potential bias in these estimates.
The stage one IV regression analysis confirmed a strong relationship
between the instrument (provisional diagnosis) and being offered a
POCT (Table S5, supplementary materials). The second stage of the IV
regression analysis (Table 3) shows the impact of the POCT on costs,
and indicates that patients who had a POCT on average cost 67 % less
than those who did not (average cost reduction: £2066: 95 % CI £624 -
£2665). Other co-variates, including moderate to high NEWS at arrival,
presence of ≥1 comorbidity, and age ≥70 years, increase overall costs
across both cohorts (p < 0.05).
The secondary analysis (OLS regression against baseline character-
istics only) indicates similar but smaller cost reductions (average re-
duction 27 % or £830; 95 % CI 2 %–46 %, or £54 - £1409) (Table S6
supplementary materials). The results from a further analysis where
costs were imputed for 13 patients with missing inpatient care costs
showed no difference in our findings (analysis available on request).
Table 1
Baseline characteristics of intervention and control cohorts.
Variable Controls n=104 Intervention n=204 t-test/ proportion test/ Wilcoxon rank-sum test as appropriate (Pr(|T| > |t|))
Demographics
Age in years (CI) 64.19 (59.96–68.42) 65.50 (62.68–68.32) −1.313 (0.601)
% Sex= female (SE) 62.5 (4.7) 60.3 (3.4) 2.2 (0.707)
National Early Warning Score (NEWS)
on arrival to ED % NEWS > 5 (SE) 21.2 (4.0) 31.86 (3.3) −10.71 (0.048)
Comorbidities
% who had ≥ 1 comorbidity (SE) 88.46 (3.31) 90.19 (2.08) −1.73 (0.637)
% with chronic lung disease (SE) 40.38 (4.81) 49.02 (3.50) −8.63 (0.150)
Provisional diagnosis
% Respiratory tract disease (SE) 33.65 (4.63) 61.27 (3.41) −27.62 (0.000)
% Other (SE) 66.35 (4.63) 38.73 (3.41) 27.62 (0.000)




Final diagnoses, antiviral prescriptions, inpatient care and length of stay.
Variable Controls (n=104) Intervention (n= 204) t-test/ proportion test/ rank-sum as appropriate (Pr(|T| > |t|))
% Influenza 37.5 (39/104) 41.67 (85/204)* −4.17 (0.481)
% Other respiratory virus 6.73 (7/104) 11.76 (24/204) −5.03 (0.165)
% Negative respiratory sample 55.77 (58/104) 46.57 (95/204) 9.20 (0.127)
% Prescribed antiviral (oseltamivir) 37.5 (39/104)** 26 (53/204)*** 11.52 (0.037)
% Inpatient care (SE) 91.3 (2.76) 74.5 (3.05) 16.8 (0.000)
% ICU (intensive care unit) stay (SE) 6.73 (2.46) 2.45 (1.08) 4.28 (0.066)
% HDU (high dependency unit) stay (SE) 5.77 (2.29) 5.39 (1.58) 0.38 (0.891)
Length of stay in days (CI) 11.49 (8.6–14.3) 6.49 (5.1–7.8) 5.00 (0.000)
Pr(|T|> |t|) in bold represent significant at a 95 or 90 % level.
CI= confidence interval.
SE= standard error.
* 76 patients tested positive for influenza by POCT, of which 56 were confirmed by secondary laboratory testing. The remaining 9 patients were assigned a
diagnosis of influenza based on the final working diagnosis at discharge. A detailed description of how final diagnoses were assigned and the antiviral prescribing
processes can be found in the supplementary materials.
** 30 had a confirmed diagnosis of influenza.
*** 51 had a confirmed diagnosis of influenza.
Table 3
Stage II IV regression analysis.
Effect on Cost for Different Covariates (IV regression) - Stage II
Value (Co-efficient) Standard Error P> |z|
POCT −1.105 0.449 0.014
Age (40–70 years) 0.403 0.239 0.091
Age (over 70 years) 0.831 0.244 0.001
Sex 0.144 0.138 0.295
NEWS Score (> 4) 0.584 0.160 0.000
Comorbidity 0.567 0.278 0.041
Chronic Lung Disease 0.225 0.154 0.145
Intercept 6.593 0.420 0.000
Wald chi2(7)= 63.11 (Prob > chi2= 0.0000)
Total costs have been transformed to logarithmic form. Regression has been
adjusted to produce robust SE estimations. Instrumented variable POCT;
n=291 (13 cases with missing inpatient care costs and 4 cases with missing
arrival NEWS score).
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4. Discussion
POC testing allows physicians to rapidly and accurately identify
influenza. This permits timely targeted treatments and implementation
of infection control measures which might previously have been de-
layed or prolonged unnecessarily. Furthermore, rapid results should
positively impact on length of stay. The introduction of influenza POC
testing in an ED at Leeds Teaching Hospitals prompted this retro-
spective evaluation of its cost impact, using individual patient level
costing data.
Our analysis demonstrates the provisional diagnosis variable is
likely to influence the decision to offer a POCT. The POCT in turn is
likely to influence the decision to discharge or admit a patient, and the
related treatment choices. If influenza is detected and treated, the
average length of stay is expected to be shorter, therefore overall costs
are expected to reduce.
The initial OLS analysis indicated POCT use is linked to increased
overall treatment costs. However, as highlighted, an OLS analysis
against well-known co-variates would produce biased treatment effects
driven by the lack of randomisation in this observational dataset. An IV
analysis was able to estimate an unbiased treatment effect through
using provisional diagnosis. This process allowed us to estimate a de-
gree of causality between the POCT and the treatment pathway.
The magnitude of our results is relevant despite the potential un-
certainty (average savings per patient between £600 and £2600). The
wide confidence interval is likely related to the small sample size and
single-centre based analysis. Despite this, we consider the results to be
robust as they are supported by a second, alternative method (OLS
against baseline characteristics) which also indicates cost savings, al-
though smaller.
Other authors have previously estimated cost savings where POCTs
are used. Brooke-Pearce and Demertzi [4] retrospectively compared
outcomes of patients presenting to the ED of a UK NHS hospital with
flu-like symptoms in two consecutive seasons. Using estimated costs,
they projected POCTs would save £16,632 - £33,264 per month through
avoiding unnecessary isolation, and potentially £328,860 per month
through reduced length of stay of POCT negative patients. Davis et al.
[3] assessed the Alere™ I Influenza A/B POCT in 4 UK NHS hospitals.
They projected POCTs would avoid a minimum of 1.1 days of incorrect
isolation, saving £261,590 per 1000 patients. The test sensitivity in this
analysis was only 77 % using throat swabs, therefore Allen et al. [22]
developed a cost-consequence model for a hypothetical cohort to esti-
mate cost impacts if more sensitive nasal swabs were used. Estimated
savings were similar, at £242.73 per patient. Hansen et al. [23] con-
sidered the potential effect of POCTs on decision-making during ED
visits in Minneapolis, United States. They compared physician man-
agement plans before and after testing, finding a change in 61 % of
cases. Using a health economics model with costs derived from hospital
billing and national databases, they projected POCTs could save
$200.40/patient/ED visit.
Our estimates suggest average savings per patient of over £2,000,
which is higher than other authors. These savings can be attributed to
more targeted treatments, fewer admissions and reduced lengths of
stay. Compared to existing work completed in the UK which use esti-
mated costs [3,4,22] our results derive directly from individual patient
level data. Although the cost of the POCTs have not been included
(approximately £36 per POCT, versus approximately £25 per laboratory
test) the use of POCTs would still produce significant savings.
5. Limitations
Testing took place prospectively in consecutive patients, but the
cohorts and their data were identified retrospectively. Furthermore,
controls were selected opportunistically and pragmatically through a
‘natural experiment’ resulting from difficulties with procurement.
Although this allowed valid, real-world data to be used, there are
limitations to this approach.
Whilst both groups derive from the same influenza season, they
occurred 6 weeks apart. The intervention cohort is immediately prior to
the peak of the season when transmission intensity was highest,
meaning the groups are not fully comparable in terms of exposure.
Despite this, both are within influenza season and occurred at times
when influenza-confirmed secondary care admissions were similar
[16]. We believe our approach is preferable to using a control group
from a different influenza season.
The control group comprised largely of patients who were admitted
and subsequently received laboratory-based testing. It is highly prob-
able that patients were presenting to ED during the ‘control period’ with
influenza-like symptoms, but were discharged without testing as they
were not sufficiently unwell for admission. These patients would not
have been identified and therefore not included in our analysis. This
could potentially produce an overestimation in our analysis of the cost-
savings.
We used pharyngeal samples instead of nasopharyngeal, which may
have led to loss of sensitivity [24,25]. However, we felt this was out-
weighed by the benefits of pharyngeal sampling as discussed in the
methods. Real-time PCR was our chosen gold standard for influenza
detection due to its sensitivity and wide availability. However, we ac-
knowledge this is a departure from viral culture or paired serum anti-
body titres which are traditionally used as gold standards.
Our analysis does not account for infection prevention and control
(IPC) aspects, largely because this was difficult to accurately evaluate
retrospectively. However, other groups have found POCTs to have a
positive impact on nosocomial influenza rates and single-room bed days
[3,5], so it could be assumed that our cost savings would only increase
if IPC aspects were incorporated.
Finally, our retrospective observational analysis is based on a single-
centre. Although we would expect similar results from other similar UK
centres, a prospective randomised multi-centre analysis would be de-
sirable to estimate the overall benefits to the NHS.
6. Conclusions
Point of care testing allows rapid and accurate influenza diagnosis,
which has been shown to reduce lengths of stay, facilitate targeted
treatments and promote correct isolation. These improvements would
be expected to reduce overall costs, which is of key importance in
healthcare settings. Our study using individual patient level costing
data has confirmed the estimated work of previous authors that POC
influenza testing in the ED would produce cost savings.
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